Search

Displaying results 1241 - 1250 of 1993 in total
  1. Target

    Tumor necrosis factor receptor superfamily member 18

    go.drugbank.com/bio_entities/BE0010519
    TargetHumans

    Receptor for TNFSF18. Seems to be involved in interactions between activated T-lymphocytes and endothelial cells and in the regulation of T-cell receptor-mediated cell death.

    Polypeptides: Tumor necrosis factor receptor superfamily member 18Synonyms: Activation-inducible TNFR family receptor
  2. Target

    Low-density lipoprotein receptor-related protein 6

    go.drugbank.com/bio_entities/BE0012061
    TargetHumans

    Component of the Wnt-Fzd-LRP5-LRP6 complex that triggers beta-catenin signaling through inducing aggregation of receptor-ligand complexes into ribosome-sized signalosomes (PubMed:11357136, PubMed:11448771

    Polypeptides: Low-density lipoprotein receptor-related protein 6
  3. Target

    Tyrosine-protein phosphatase non-receptor type 2

    go.drugbank.com/bio_entities/BE0012706
    TargetHumans

    May also regulate the hepatocyte growth factor receptor signaling pathway through dephosphorylation of the hepatocyte growth factor receptor MET. Also plays an important role in glucose homeostasis. … Non-receptor type tyrosine-specific phosphatase that dephosphorylates receptor protein tyrosine kinases including INSR, EGFR, CSF1R, PDGFR.

    Polypeptides: Tyrosine-protein phosphatase non-receptor type 2
  4. Target

    Tumor necrosis factor receptor superfamily member EDAR

    go.drugbank.com/bio_entities/BE0021253
    TargetHumans

    Receptor for EDA isoform A1, but not for EDA isoform A2. Mediates the activation of NF-kappa-B and JNK. May promote caspase-independent cell death

    Polypeptides: Tumor necrosis factor receptor superfamily member EDARSynonyms: EDA-A1 receptor, Ectodysplasin-A receptor
  5. Target

    T cell receptor beta variable 6-5

    go.drugbank.com/bio_entities/BE0021562
    TargetHumans

    V region of the variable domain of T cell receptor (TR) beta chain that participates in the antigen recognition (PubMed:24600447).

    Polypeptides: T cell receptor beta variable 6-5
  6. Drug

    Erlotinib

    go.drugbank.com/drugs/DB00530
    ApprovedInvestigational

    Recent studies demonstrate that erlotinib is also a potent inhibitor of JAK2V617F, which is a mutant form of tyrosine kinase JAK2 found in most patients with polycythemia vera (PV) and a substantial proportion … Erlotinib binds to the epidermal growth factor receptor (EGFR) tyrosine kinase in a reversible fashion at the adenosine triphosphate (ATP) binding site of the receptor.

    Categories: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors
  7. Drug

    Flufenamic acid

    go.drugbank.com/drugs/DB02266
    Approved

    (From Martindale, The Extra Pharmacopoeia, 30th ed, p16)

  8. Drug

    Xylose

    go.drugbank.com/drugs/DB09419
    ApprovedWithdrawn

    Xylose is a monosaccharide of the aldopentose type consisted of five carbon atoms and an aldehyde functional group. Xylose is a sugar isolated from wood. D-Xylose is a sugar widely used as a diabetic sweetener in food and beverage. Xylos...

  9. Drug

    Adenosine phosphate

    go.drugbank.com/drugs/DB00131
    ApprovedInvestigationalNutraceuticalWithdrawn

    Adenosine phosphate, or adenylic acid, is an adenine nucleotide containing one phosphate group esterified to the sugar moiety in the 2'-, 3'-, or 5'-position. Adenosine phosphate was withdrawn by the FDA since it was considered neither s...

  10. Drug

    Alendronic acid

    go.drugbank.com/drugs/DB00630
    ApprovedInvestigational

    Alendronic acid is a second generation bisphosphonate that is used for the treatment of some forms of osteoperosis and Paget's disease[FDA Label] . It functions by preventing resorption of bone[FDA Label] .